Systemic chemotherapy in addition to CRS-HIPEC for colorectal peritoneal metastases: A critical systematic review on the impact on overall survival.

Autor: van den Heuvel TBM; Department of Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.; Department of Oncology and Developmental Biology (GROW), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands., Lurvink RJ; Department of Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands., Rovers KPB; Department of Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands., van Hellemond IEG; Department of Medical Oncology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands., de Hingh IHJT; Department of Surgery, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.; Department of Oncology and Developmental Biology (GROW), Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands.; Department of Research & Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.
Jazyk: angličtina
Zdroj: Journal of surgical oncology [J Surg Oncol] 2024 Sep 11. Date of Electronic Publication: 2024 Sep 11.
DOI: 10.1002/jso.27849
Abstrakt: In patients with resectable colorectal peritoneal metastases, it is unclear whether systemic chemotherapy, in addition to cytoreductive surgery-hyperthermic intraperitoneal chemotherapy (CRS-HIPEC), improves overall survival (OS). This systematic review of 12 retrospective studies involving 3721 patients aimed to summarize the available evidence. Contradictory results were found regarding the effectiveness of neoadjuvant, adjuvant, and perioperative systemic therapies on OS, with a high risk of bias. Available evidence remains inconclusive, stressing the need for prospective, randomized trials, like the ongoing Dutch CAIRO6-trial.
(© 2024 The Author(s). Journal of Surgical Oncology published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: